Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 8, 2007 Brian Orelli	Is Indevus Headed to the Black? Two new drugs should help turn things around at specialty pharmaceutical company Indevus. The company is not in the black yet, but they have been on a roll these last three months with FDA approvals of two new drugs.
Chemistry World June 24, 2015 Matthew Gunther	Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal.
The Motley Fool December 18, 2007 Brian Lawler	PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
The Motley Fool February 6, 2008 Brian Lawler	PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note.
The Motley Fool January 26, 2005 Charly Travers	Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock.
The Motley Fool May 27, 2009 Brian Orelli	A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news.
The Motley Fool June 5, 2008 Brian Lawler	Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool October 31, 2007 Brian Lawler	Depomed Plays Hot Potato Following disappointing sales numbers, King Pharmaceuticals and Depomed terminate their marketing collaboration deal.
The Motley Fool January 31, 2007 Brian Lawler	No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now.
The Motley Fool August 29, 2007 Brian Lawler	PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors.
Chemistry World April 29, 2014 Phillip Broadwith	Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time.
The Motley Fool July 14, 2005 Charly Travers	Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders.
CRM February 2003 David Myron	Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place.
The Motley Fool September 12, 2008 Brian Lawler	A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches.
Chemistry World June 10, 2008 James Mitchell Crow	A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker.
The Motley Fool April 14, 2008 Brian Lawler	PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business.
The Motley Fool March 2, 2011 Susmita Chatterjee	How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others?
The Motley Fool April 8, 2004 Charly Travers	Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal.
The Motley Fool March 15, 2005 Charly Travers	PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note.
The Motley Fool November 22, 2006 Brian Lawler	Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news.
Chemistry World July 29, 2015 Katrina Megget	Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell.
The Motley Fool October 7, 2009 Jim Mueller	Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble.
The Motley Fool June 3, 2004 Charly Travers	New Chapter for Indevus The drug company Indevus puts troubled history behind it with the launch of the drug Sanctura which is now on the market for the treatment of overactive bladder.
Chemistry World January 25, 2013 Andrew Turley	Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million
The Motley Fool December 14, 2004 Charly Travers	A Stagnant Drug Stock A drug launch is not driving share price increases for Indevus.
BusinessWeek October 13, 2003 Arlene Weintraub	He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug?
The Motley Fool April 28, 2011 Brian Orelli	Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable.
The Motley Fool February 25, 2005 Charly Travers	Protein Design Labs' Future A look ahead to a transitional year -- and how much the ESP Pharma acquisition will boost revenues -- coming Monday.
The Motley Fool March 5, 2008 Brian Lawler	PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring.
The Motley Fool September 28, 2007 Brian Lawler	Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs.
The Motley Fool August 5, 2005 Charly Travers	No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders.
The Motley Fool May 30, 2008 Brian Lawler	PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs.
The Motley Fool February 27, 2007 Brian Lawler	PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note.
CIO December 14, 2010 Kim S. Nash	How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan.
Chemistry World July 28, 2014 Andy Extance	Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.
The Motley Fool May 6, 2009 Robert Steyer	Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags.
Chemistry World November 27, 2015 Anthony King	Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes.
The Motley Fool August 21, 2008 Brian Lawler	PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
Chemistry World September 10, 2015 Katrina Megget	Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions
The Motley Fool May 7, 2008 Brian Lawler	PDL Delivers a Dividend The drugmaker's investors get a hefty payout.
The Motley Fool May 12, 2008 Brian Orelli	Lowering the Barr Barr Pharmaceuticals disappoints by lowering expectations.
The Motley Fool December 29, 2008 Brian Orelli	Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes.
The Motley Fool September 26, 2007 Brian Lawler	Shareholders Pile On Against PDL Another large shareholder has come out against the status quo at PDL BioPharma. Management resignations seen as necessary by those wanting to sell or break apart the biopharma.
The Motley Fool December 16, 2005 Stephen D. Simpson	A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note.
The Motley Fool September 24, 2007 Brian Lawler	Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note.